## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Nama	$\alpha$ t	an	titi	. 7
Name	()I	CII	LI L	v

#### PULSE HEALTH LIMITED

ABN

69 104 113 760

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

<u>UNLISTED</u> PERFORMANCE RIGHTS, TRANCHE 3, EXPIRY DATE 31/12/2016 AND PRICE HURDLE \$0.72 (PHGAI)

Number of \*securities issued or to be issued (if known) or maximum number which may be issued (945,000) <u>UNLISTED</u> PERFORMANCE RIGHTS, TRANCHE 3, EXPIRY DATE 31/12/2016 AND PRICE HURDLE \$0.72 (PHGAI)

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

<u>UNLISTED</u> PERFORMANCE RIGHTS, TRANCHE 3, EXPIRY DATE 31/12/2016 AND PRICE HURDLE \$0.72

IF TRANCHE 3 PERFORMANCE CONDITION IS NOT SATISFIED ON THE TRANCHE 3 EXPIRY DATE, THEN THE TRANCHE 3 PERFORMANCE RIGHTS WILL BE DEEMED TO IMMEDIATELY LAPSE. 4 Do the +securities rank equally in N/A - NOT LISTED all respects from the +issue date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment N/A – LAPSE OF PERFORMANCE RIGHTS 5 Issue price or consideration 6 Purpose of the issue UNDER TERMS AND CONDITIONS OF (If issued as consideration for the UNLISTED PERFROMANCE RIGHTS acquisition of assets, clearly TRANCHE 3. IF THE CONDITION IS NOT identify those assets) SATISFIED ON THE TRANCHE 3 EXPIRY DATE, THEN THE TRANCHE 3 PERFORMANCE RIGHTS WILL BE DEEMED TO IMMEDIATELY LAPSE. IT IS NOTED THAT THE ORIGINAL SECURITIES (TRANCHE 1, 2, AND 3 RIGHTS) WITH THESE TERMS AND CONDITIONS WERE APPROVED BY SHAREHOLDERS ON 26 MAY 2014 6a Is the entity an +eligible entity that No has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed 6с Number of +securities issued N/A without security holder approval under rule 7.1 Number of +securities issued with 6d N/A security holder approval under rule 7.1A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	<sup>+</sup> Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	EXPIRY DATE 31 DEC	CEMBER 2016
8	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)	Number 257,079,905	+Class ORDINARY SHARES

9	Number	and	+class	of	all
	+securities	not	quoted	on	ASX
	(including	the +s	ecurities	in se	ection
	2 if applica	ıble)			

Number	+Class
945,000 (945,000)	TRANCHE 3 PERFORMANCE RIGHTS (PHGAI)
= 0	
315,000	TRANCHE 4 PERFORMANCE RIGHTS (PHGAI)
500,000	B Class Options (PHGAA)
500,000	C Class Options (PHGAA)
1	

10	Dividend policy (in the case of a
	trust, distribution policy) on the
	increased capital (interests)

N/A			

## Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	

33	<sup>+</sup> Issue	date	
	•	uotation of securities	
34	Type of	of <sup>+</sup> securities <i>ne</i> )	
(a)		<sup>+</sup> Securities described in Part 1	
(b)			of the escrowed period, partly paid securities that become fully paid, employed ds, securities issued on expiry or conversion of convertible securities
Entiti	es that	t have ticked box 34(a)	
Addit	ional s	ecurities forming a new cla	ss of securities
Tick to docume		you are providing the informati	ion or
35		= -	securities, the names of the 20 largest holders of the number and percentage of additional *securities held by
36		If the *securities are *equity *securities setting out the numb 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	securities, a distribution schedule of the additional per of holders in the categories
37		A copy of any trust deed for th	e additional <sup>+</sup> securities
Entiti	es that	t have ticked box 34(b)	
38		er of <sup>+</sup> securities for which ation is sought	
39		s of *securities for which ion is sought	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Descen for request for quotation		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)		

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	
Print name:	David Franks
	== == == ==

## Appendix 3B – Annexure 1

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figures capacity is calculated	ure from which the placement	
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	231,120,579	
Add the following:		
Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2	25,959,326	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	0	
"A"	257,079,905	

04/03/2013 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	38,561,985	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	0	
Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	0	
Step 4: Subtract "C" from ["A" x "l placement capacity under rule 7.1	B"] to calculate remaining	
"A" x 0.15	38,561,985	
Note: number must be same as shown in Step 2		
Subtract "C"	0	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	38,561,985	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	NI/A	
"E"	N/A	

04/03/2013 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	N/A	
Note: number must be same as shown in Step 2		
Subtract "E"	N/A	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	N/A	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.